All In Biotech

Drug Trial Radar · NCT00099268

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

Last checked: Nov 19, 2026Latest source record: Apr 23, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 747 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

747

Actual

Start

Sep 2004

Primary completion

Nov 2008

Study completion Nov 2008

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
Collaborators
Orion Corporation, Orion Pharma
First posted
Dec 10, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 30 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.

Conditions

  • Parkinson's Disease

Interventions

  • Carbidopa/levodopa/entacaponeDrug

    Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.

  • Immediate release carbidopa/levodopaDrug

    Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of DyskinesiaTime frame: Treatment duration for an individual patient varied between a minimum of 134 weeks for those patients recruited last and a maximum of 208 weeks for those patients recruited first

Locations

73 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic

    Scottsdale, Arizona

  • Coastal Neurological Medical Group

    La Jolla, California

  • Keck School of Medicine, Division of Movement Disorders

    Los Angeles, California

  • Reed Neurological Research Center

    Los Angeles, California

  • The Parkinson's Institute

    Sunnyvale, California

  • Molecular NeuroImaging, LLC

    New Haven, Connecticut

  • Parkinson's Disease and Movement Disorder Center

    Boca Raton, Florida

  • University of Miami

    Miami, Florida

  • Charlotte Neurological Service

    Port Charlotte, Florida

  • University of South Florida

    Tampa, Florida

  • Wesley Woods Health Center

    Atlanta, Georgia

  • Medical College of Georgia

    Augusta, Georgia

  • Northwestern University Medical School

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Landon Center on Aging

    Kansas City, Kansas

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Boston University School of Medicine

    Boston, Massachusetts

  • Clinical Neuroscience Center

    Southfield, Michigan

  • Parkinson's Disease and Movement Disorder Center of Albany Medical

    Albany, New York

  • Parkinson's Disease and Movement Disorders Center of Long Island

    Commack, New York

  • Mount Sinai School of Medicine

    New York, New York

  • Columbia University, Neurological Institute

    New York, New York

  • University of Rochester

    Rochester, New York

  • Duke University Medical Center Movement Disorders Center

    Durham, North Carolina

  • Pennsylvania Neurology Institute

    Philadelphia, Pennsylvania

  • NeuroHealth, Inc.

    Warwick, Rhode Island

  • Semmes-Murphey Clinic

    Memphis, Tennessee

  • University of Texas Southwestern Medical Center at Dallas

    Dallas, Texas

  • Baylor College of Medicine, Parkinson's Disease Center

    Houston, Texas

  • Wisconsin Institute for Neurologic and Sleep Disorders

    Milwaukee, Wisconsin

  • Novartis Investigative Site

    Innsbruck, Austria

  • Novartis Investigative Site

    Antwerp, Belgium

  • Novartis Investigative Site

    Bruges, Belgium

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

  • Novartis Investigative Site

    London, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Helsinki, Finland

  • Novartis Investigative Site

    Kuopio, Finland

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.